Senior Scientific Staff
Andrew Cherniack, PhD
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Jon Goldstein, PhD
Research Scientist II
2014-
PhD, University of Wisconsin - Madison
Phone|Email|LinkedIn
My focus is to understand the biochemical and cellular consequences of genomic alterations in cancer. My goal is to translate these findings into targeted therapeutic candidates.
Research Scientist II
2014-
PhD, University of Wisconsin - Madison
Phone|Email|LinkedIn
My focus is to understand the biochemical and cellular consequences of genomic alterations in cancer. My goal is to translate these findings into targeted therapeutic candidates.
Heidi Greulich, PhD
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Jodi Hirschman, PhD
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Sooncheol (Charlie) Lee, PhD
Research Scientist II
2020-
PhD, Korea Advanced Institute of Science and Technology, South Korea
Phone|Email|LinkedIn
My research focuses on how RNA-binding proteins regulate gene expression post-transcriptionally and their role in the survival of cancer cells. My long-term goal is to induce apoptosis of cancer cells by targeting RNA-binding proteins or post-transcriptional regulation.
Research Scientist II
2020-
PhD, Korea Advanced Institute of Science and Technology, South Korea
Phone|Email|LinkedIn
My research focuses on how RNA-binding proteins regulate gene expression post-transcriptionally and their role in the survival of cancer cells. My long-term goal is to induce apoptosis of cancer cells by targeting RNA-binding proteins or post-transcriptional regulation.
Yvonne Li, PhD, FACMG
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
Gizem Karsli Uzunbas, PhD
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Xiaoyun Wu, PhD
Lead Scientist/Group Leader
2014-
PhD, Wadsworth Center, SUNY Albany and NY State Department of Health
Email|LinkedIn
I am passionate about developing new cancer therapies based on genome-inspired targets. I use traditional and genomic tools to identify potential patient populations and to understand the mechanism of action for promising anti-cancer agents.
Lead Scientist/Group Leader
2014-
PhD, Wadsworth Center, SUNY Albany and NY State Department of Health
Email|LinkedIn
I am passionate about developing new cancer therapies based on genome-inspired targets. I use traditional and genomic tools to identify potential patient populations and to understand the mechanism of action for promising anti-cancer agents.
Junior Scientific Staff
Alyssa Fishbein, B.A.
Research Technician
2019-
B.A., Wellesley College
I work on innate immune signaling, specifically of RNA metabolism, in cancer cells with an ultimate goal of identifying potential novel therapeutic targets.
Research Technician
2019-
B.A., Wellesley College
I work on innate immune signaling, specifically of RNA metabolism, in cancer cells with an ultimate goal of identifying potential novel therapeutic targets.
Hersh Gupta, A.B.
Associate Computational Biologist
2020-
B.A., Brown University
I work with physicians across DFCI, the Broad, and other organizations to analyze clinical targeted sequencing data using OncoPanel. I focus on the use of rigorous computational and statistical methods to answer both clinical and basic science questions.
Associate Computational Biologist
2020-
B.A., Brown University
I work with physicians across DFCI, the Broad, and other organizations to analyze clinical targeted sequencing data using OncoPanel. I focus on the use of rigorous computational and statistical methods to answer both clinical and basic science questions.
Stephanie Hoyt, B.A.
Associate Computational Biologist
2020-
B.A., Cornell University
I work on the discovery of new targets for cancer treatments.
Associate Computational Biologist
2020-
B.A., Cornell University
I work on the discovery of new targets for cancer treatments.
Lauren Kageler, B.S.
Research Associate
2020-
B.S., Dickinson College
My work is focused on validating telomerase as a therapeutic target in models of glioblastoma and other cancer types; and generating novel biochemical tools for a telomerase drug discovery effort.
Research Associate
2020-
B.S., Dickinson College
My work is focused on validating telomerase as a therapeutic target in models of glioblastoma and other cancer types; and generating novel biochemical tools for a telomerase drug discovery effort.
Joseph McGaunn, B.S.
Research Associate
2020-
B.S., University of Massachusetts Amherst
Email|LinkedIn|Twitter
I am working to understand the mechanism of action of novel cancer therapeutics and identify patient populations that may benefit from these drugs. One of my current focuses is a novel class of small molecules that target cancers expressing high levels of PDE3A and SLFN12. In addition, I am also exploring small molecules that target epigenetic regulators.
Research Associate
2020-
B.S., University of Massachusetts Amherst
Email|LinkedIn|Twitter
I am working to understand the mechanism of action of novel cancer therapeutics and identify patient populations that may benefit from these drugs. One of my current focuses is a novel class of small molecules that target cancers expressing high levels of PDE3A and SLFN12. In addition, I am also exploring small molecules that target epigenetic regulators.
Brianna Silverman, B.S.
Research Technician
2019-
B.S., Brandeis University
I assist in experiments focused on uncovering mechanisms of resistance to receptor tyrosine kinase inhibitors in lung cancer. I am currently investigating resistance and sensitivity to EGFR inhibitors.
Research Technician
2019-
B.S., Brandeis University
I assist in experiments focused on uncovering mechanisms of resistance to receptor tyrosine kinase inhibitors in lung cancer. I am currently investigating resistance and sensitivity to EGFR inhibitors.
Stephanie Tang, A.B.
Research Associate
2020-
A.B., Harvard College
I am interested in exploring the genetic underpinnings of cancer and translating these findings into potential therapies.
Research Associate
2020-
A.B., Harvard College
I am interested in exploring the genetic underpinnings of cancer and translating these findings into potential therapies.